Tenofovir alafenamide Fumarate: Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.
Study summary
This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Positive hepatitis b surface antigen and hepatitis b antibody \> 0.5 year;
* Age from 18 to 65 years old;
* Serum Alanine Aminotransferase(ALT) ≤1×ULN at least 12 weeks;
* Positive Hepatitis b virus(HBV);
* Do not receive nucleotide/nucleoside analogues or interferon treatment in the past half year.
Exclusion Criteria:
* Other active liver diseases;
* Hepatocellular carcinoma or other malignancy;
* Pregnancy or lactation;
* Human immunodeficiency virus infection or congenital immune deficiency diseases; 5.Severe diabetes, autoimmune diseases; 6.Other important organ dysfunctions; 7.Using glucocorticoid; 8.Patients can not follow-up; 9.Investigator considering inappropriate.
Primary outcome measure(s)
hepatitis b s antigen decrease from baseline — 48 week, 96 week, 144 week Magnitude of decrease in hepatitis B antigen quantification from baseline to week 144.
Trial sites (1)
Facility
City
Region
Status
Third Affiliated Hospital of Sun Yat-sen University
Guangzhou
Guangdong
Recruiting
More Third Affiliated Hospital, Sun Yat-Sen University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.